Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
Joséphine Carpentier,Iuliia Pavlyk,Uma Mukherjee,Peter E Hall,Peter W Szlosarek
DOI: https://doi.org/10.2147/LCTT.S335117
2022-09-06
Lung Cancer: Targets and Therapy
Abstract:Joséphine Carpentier, 1 Iuliia Pavlyk, 1 Uma Mukherjee, 2 Peter E Hall, 2 Peter W Szlosarek 1, 2 1 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, UK; 2 Department of Medical Oncology, Barts Health NHS Trust, St. Bartholomew's Hospital, London, EC1A 7BE, UK Correspondence: Peter W Szlosarek, Centre for Molecular Oncology, Queen Mary University of London, Charterhouse Square, London, EC1M 6BG, United Kingdom, Tel +44 0 20 7882 3559, Fax +44 0 20 7882 3884, Email Arginine deprivation has gained increasing traction as a novel and safe antimetabolite strategy for the treatment of several hard-to-treat cancers characterised by a critical dependency on arginine. Small cell lung cancer (SCLC) displays marked arginine auxotrophy due to inactivation of the rate-limiting enzyme argininosuccinate synthetase 1 (ASS1), and as a consequence may be targeted with pegylated arginine deiminase or ADI-PEG20 (pegargiminase) and human recombinant pegylated arginases (rhArgPEG, BCT-100 and pegzilarginase). Although preclinical studies reveal that ASS1-deficient SCLC cell lines are highly sensitive to arginine-degrading enzymes, there is a clear disconnect with the clinic with minimal activity seen to date that may be due in part to patient selection. Recent studies have explored resistance mechanisms to arginine depletion focusing on tumor adaptation, such as ASS1 re-expression and autophagy, stromal cell inputs including macrophage infiltration, and tumor heterogeneity. Here, we explore how arginine deprivation may be combined strategically with novel agents to improve SCLC management by modulating resistance and increasing the efficacy of existing agents. Moreover, recent work has identified an intriguing role for targeting arginine in combination with PD-1/PD-L1 immune checkpoint inhibitors and clinical trials are in progress. Thus, future studies of arginine-depleting agents with chemoimmunotherapy, the current standard of care for SCLC, may lead to enhanced disease control and much needed improvements in long-term survival for patients. Keywords: small cell lung cancer, SCLC, arginine, argininosuccinate synthase 1, ASS1, arginine deprivation, tumor microenvironment, immunotherapy Small cell lung cancer (SCLC) is a notoriously lethal subtype of smoking-related thoracic cancer, accounting for 10–15% of global lung cancer incidence with a 5-year survival rate of less than 7%. 1 Treatments for SCLC have advanced slowly in the last few decades with much scope for improvement. Harnessing fundamental and novel biological insights will be critical to transforming the SCLC therapeutic landscape. Derived from neuroendocrine precursor cells, SCLC is characterised by rapid tumor growth, genomic instability and early metastatic spread underlying the poor survival outcomes. 2,3 On a molecular level, in addition to universal TP53 and RB1 inactivation, SCLC is classified into four distinct subtypes according to the expression of ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P) or YAP1 (SCLC-Y). 4,5 This molecular reappraisal of SCLC offers the possibility of novel personalised therapies. Inducing arginine deprivation is a promising therapeutic strategy for multiple cancer types including SCLC that are deficient in the arginine biosynthetic enzyme argininosuccinate synthetase 1 (ASS1). In the current review, we provide an update on arginine deprivation as a specific antimetabolite therapy focusing on SCLC both as monotherapy and in combination with selected therapies based on emerging preclinical and clinical data. Arginine (2-amino-5-guanidinovaleric acid) is a semi-essential amino acid in mammalian cells. 6 As one of the 20 most common amino acids in humans, it is a highly versatile molecule serving as the precursor of key molecules such as urea, nitric oxide, proline, polyamines or proteins. 7 Additionally, arginine can trigger secretion of molecules such as growth hormones, insulin or glucagon. 8 This metabolite is a core component of the urea cycle, the only known pathway in humans capable of recycling and eliminating the nitrogen-containing molecule ammonia. 9,10 Arginine biosynthesis takes place within the urea cycle from the conversion of ornithine to citrulline in the mitochondria catalysed by the ornithine transcarbamylase (OTC) enzyme. 11 Citrulline can also be sourced from glutamine through a series of sequential intestinal enzymatic reactions which release the metabolite to the blood circulation. 12 Citrulline and aspartate undergo condensation to argininosuccinate by the ATP-dependent enzyme ASS1, the rate-limiting enzyme of the urea cycle. The last step is the conversion of -Abstract Truncated-